Clinical Trials Browser

OTHER × inavolisib × Clear all

NCT07543250 2026-04-21

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Not yet recruiting

Breast Neoplasms

NCT07522697 2026-04-13

MITO END-4

Phase 2 Not yet recruiting

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT04486352 2026-04-01

EndoMAP

Phase 1/2 Recruiting

Endometrial Neoplasms

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT07441512 2026-03-02

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Phase 2 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

Breast Neoplasms

NCT05306041 2025-02-17

GeparPiPPa

Phase 2 Recruiting

HER2-positive Breast Cancer

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

Phase 2 Completed

Neoplasm Metastasis